Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa María Biotherapeutics Inc, Amgen IncfiledCriticalSanta María Biotherapeutics Inc
Priority claimed from PCT/US2015/035818external-prioritypatent/WO2015192127A2/en
Publication of CR20160585ApublicationCriticalpatent/CR20160585A/en
Se revela en la presente una composición a base de un receptor de activina IIB y métodos de uso relacionados, por ejemplo, para tratar tumores sólidos. También se revelan métodos de preparación del compuesto y la formulación.A composition based on an activin IIB receptor and related methods of use, for example, for treating solid tumors is disclosed herein. Methods of preparation of the compound and formulation are also disclosed.
CR20160585A2014-06-132015-06-15
FORMULATED RECEPTORS POLIPEPTIDES AND RELATED METHODS
CR20160585A
(en)
Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.